Symptomatic Intracranial Atherosclerosis: Natural History of Medical Management Beyond the Hyperacute Stage of Ischemic Stroke in the Post-SAMMPRIS Era
Restricted accessResearch articleFirst published online June, 2018
Symptomatic Intracranial Atherosclerosis: Natural History of Medical Management Beyond the Hyperacute Stage of Ischemic Stroke in the Post-SAMMPRIS Era
Background: A major cause of ischemic stroke (IS) worldwide, especially in Asia, is intracranial atherosclerotic stenosis (ICAS), which is also associated with the high risk of recurrent stroke.
Objective: The aim of our study was to determine the natural history of symptomatic ICAS ischemic stroke (ICAS IS) patients.
Materials and Methods: We collected data on acute ICAS IS patients beyond the hyperacute IS phase to determine stroke recurrence and mortality at a tertiary care neurology hospital. Data were collected on basic demographics and traditional risk factors such as hypertension, coronary artery disease, diabetes mellitus, tobacco abuse, and hyperlipidemia, and statistical analysis was done. The primary endpoint was to measure the unfavorable outcome as defined by recurrent stroke or death from any cause.
Results: The mean follow-up time for the total 87 patients was 24.5 months. Nine patients (10.3%) had an unfavorable outcome in the follow-up period; 2 (2.3%) of them had recurrent IS. Age was a predictor of the unfavorable outcome (P = .0025), whereas hyperlipidemia was present more in patients with the favorable outcome (P = .033). There was a tendency for patients with poor outcomes to have a higher National Institutes of Health Stroke Scale at their onset of stroke.
Conclusions: Aggressive medical treatment was associated with a relatively low risk of recurrent stroke in our ICAS IS population. This study provides groundwork for larger studies that can take into account clinical and newer imaging techniques to improve secondary prevention in ICAS IS patients.
Gorelick PBWongKSBae HJPandeyDK. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke. 2008;39(8):2396–2399.
2.
ChimowitzMIKokkinosJStrongJ. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology. 1995;45(8):1488–1493.
3.
Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Stroke. 1998;29(7):1389–1392.
4.
WongLK. Global burden of intracranial atherosclerosis. Int J Stroke. 2006;1(3):158–159.
5.
WangYZhaoXLiuLfor CICAS Study Group. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study. Stroke. 2014;45(3):663–669.
6.
KateMSylajaPNKesavadasCThomas.BImaging and clinical predictors of unfavorable outcome in medically treated symptomatic intracranial atherosclerotic disease. J Stroke Cerebrovasc Dis. 2014;23(5):973–978.
7.
ChimowitzMILynnMJDerdeynCP; for SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11): 993–1003.
8.
Kasner SEChimowitzMILynnMJ; for Warfarin Aspirin Symptomatic Intracranial Disease Trial Investigators. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation. 2006;113(4):555–563.
9.
KhanAKasnerSELynnMJChimowitzMI. Risk factors and outcome of patients with symptomatic intracranial stenosis presenting with lacunar stroke. Stroke. 2012;43(5):1230–1233.
10.
WongKSCaplanLRKimJS. Stroke mechanisms. Front Neurol Neurosci.2016;40:58–71.
11.
SamuelsOBJosephGJLynnMJSmithHAChimowitzMI. A standardized method for measuring intracranial arterial stenosis. AJNR Am J Neuroradiol. 2000;21(4):643–646.
12.
López-CancioIMatheusMGRomanoJG.; for the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Infarct patterns, collaterals and likely causative mechanisms of stroke in symptomatic intracranial atherosclerosis. Cerebrovasc Dis. 2014;37(6):417–422.
13.
KernanWNOvbiageleBBlackHR; for American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease . Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236.
14.
MazighiMTanasescuRDucrocqX. Prospective study of symptomatic atherothrombotic intracranial stenosis: the GESICA study. Neurology. 2006;66(8):1187–1191.
15.
ChimowitzMILynnMJHowlett-SmithH; for Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305–1316.
16.
SanghaRSNaidechAMCoradoCAnsariSAPrabhakaranS. Challenges in the medical management of symptomatic intracranial stenosis in an urban setting. Stroke. 2017;48(8):2158–2163.
17.
DerdeynCPChimowitzMILynnMJ; for Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014;383(9914):333–341.
